{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:26:15Z","timestamp":1788272775695,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.euroneuro.2025.112746","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T10:45:29Z","timestamp":1768560329000},"page":"112746","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Bridging the reporting gap: Application of the ReSPCT guidelines in psilocybin clinical trial protocols"],"prefix":"10.1016","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5648-4652","authenticated-orcid":false,"given":"Damian","family":"Swieczkowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4061-775X","authenticated-orcid":false,"given":"Aleksander","family":"Kwa\u015bny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Sadko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6343-8454","authenticated-orcid":false,"given":"Wies\u0142aw Jerzy","family":"Cuba\u0142a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2025.112746_bib0001","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1089\/psymed.2023.0007","article-title":"A systematic review of reporting practices in psychedelic clinical trials: psychological support, therapy, and psychosocial interventions","volume":"1","author":"Brennan","year":"2023","journal-title":"Psychedelic Med."},{"key":"10.1016\/j.euroneuro.2025.112746_bib0002","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1192\/j.eurpsy.2023.2479","article-title":"The new European Medicines Agency guideline on antidepressants: a guide for researchers and drug developers","volume":"67","author":"Butlen-Ducuing","year":"2023","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.112746_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2022.887255","article-title":"Psychedelic-assisted Psychotherapy\u2014A systematic review of associated psychological interventions","volume":"13","author":"Cavarra","year":"2022","journal-title":"Front. Psychol."},{"key":"10.1016\/j.euroneuro.2025.112746_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.nsa.2024.103938","article-title":"Knowledge gaps in psychedelic medicalisation: clinical studies and regulatory aspects","volume":"3","author":"E-Wen McCulloch","year":"2024","journal-title":"Neurosci. Appl."},{"key":"10.1016\/j.euroneuro.2025.112746_bib0004","doi-asserted-by":"crossref","DOI":"10.1177\/00221678221085800","article-title":"Integration in Psychedelic-Assisted treatments: recurring themes in current providers\u2019 Definitions, challenges, and concerns","author":"Earleywine","year":"2022","journal-title":"J. Humanist. Psychol."},{"issue":"9","key":"10.1016\/j.euroneuro.2025.112746_bib0005","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1177\/02698811251338214","article-title":"Set and setting of psychedelics for therapeutic use in psychiatry: a systematic review","volume":"39","author":"Estric","year":"2025","journal-title":"J. Psychopharmacol. (Oxf.)"},{"key":"10.1016\/j.euroneuro.2025.112746_bib0023","unstructured":"Food and Drug Administration, 2023. Psychedelic drugs: considerations for clinical investigations. Guidance for industry (Draft Guidance). U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, MD. Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/psychedelic-drugs-considerations-clinical-investigations (accessed 14 December 2025)."},{"key":"10.1016\/j.euroneuro.2025.112746_bib0007","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/7854_2021_298","article-title":"Effects of setting on psychedelic experiences, therapies, and outcomes: a rapid scoping review of the literature","volume":"56","author":"Golden","year":"2022","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"10.1016\/j.euroneuro.2025.112746_bib0008","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.euroneuro.2025.11.007","article-title":"Psychedelics: the pathway to implementation in the European healthcare systems","volume":"102","author":"Gr\u00fcnder","year":"2026","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.112746_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2025.116359","article-title":"A systematic review of participant diversity in psychedelic-assisted psychotherapy trials","volume":"345","author":"Haft","year":"2025","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2025.112746_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2023.115531","article-title":"Psilocybin-assisted therapy for depression: a systematic review and meta-analysis","volume":"329","author":"Haikazian","year":"2023","journal-title":"Psychiatry Res."},{"issue":"2","key":"10.1016\/j.euroneuro.2025.112746_bib0011","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00213-017-4820-5","article-title":"The hidden therapist: evidence for a central role of music in psychedelic therapy","volume":"235","author":"Kaelen","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2025.112746_bib0012","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.21037\/apm-24-35","article-title":"Psilocybin-assisted psychotherapy for existential distress: practical considerations for therapeutic application-a review","volume":"13","author":"Kim","year":"2024","journal-title":"Ann. Palliat. Med."},{"key":"10.1016\/j.euroneuro.2025.112746_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1477996","article-title":"Short-term safety and tolerability profile of 5-methoxy-N,N-dimethyltryptamine in human subjects: a systematic review of clinical trials","volume":"15","author":"Kwa\u015bny","year":"2024","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.112746_bib0016","article-title":"Current perspectives on psychedelic treatments in Europe","volume":"61","author":"Madero","year":"2025","journal-title":"Lancet Reg. Health \u2013 Eur."},{"issue":"6643","key":"10.1016\/j.euroneuro.2025.112746_bib0014","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1126\/science.adg1324","article-title":"Pressing regulatory challenges for psychedelic medicine","volume":"380","author":"McGuire","year":"2023","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.euroneuro.2025.112746_bib0015","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1556\/2054.2025.00457","article-title":"Tuning in: psychedelics and music","volume":"9","author":"Mikosz","year":"2025","journal-title":"J. Psychedelic. Stud."},{"key":"10.1016\/j.euroneuro.2025.112746_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2025.1652568","article-title":"Psychedelic minimalism: the case against music in psychedelic therapy settings","volume":"16","author":"Nader","year":"2025","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.112746_bib0018","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.965641","article-title":"Therapeutic setting as an essential component of psychedelic research methodology: reporting recommendations emerging from clinical trials of 3,4-methylenedioxymethamphetamine for post-traumatic stress disorder","volume":"13","author":"Okano","year":"2022","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.112746_bib0019","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jamapsychiatry.2023.1554","article-title":"Importance of integrating spiritual, existential, religious, and theological components in psychedelic-assisted therapies","volume":"80","author":"Palitsky","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"9","key":"10.1016\/j.euroneuro.2025.112746_bib0020","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1177\/02698811251337372","article-title":"What are set and setting: reducing vagueness to improve research and clinical practice","volume":"39","author":"Patch","year":"2025","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.euroneuro.2025.112746_bib0021","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1186\/s12909-024-06141-3","article-title":"Expert recommendations for Germany's integration of psychedelic-assisted therapy","volume":"24","author":"Perez Rosal","year":"2024","journal-title":"BMC Med. Educ."},{"issue":"7","key":"10.1016\/j.euroneuro.2025.112746_bib0022","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/s41591-025-03685-9","article-title":"An international Delphi consensus for reporting of setting in psychedelic clinical trials","volume":"31","author":"Pronovost-Morgan","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.euroneuro.2025.112746_bib0024","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.948302","article-title":"Psychedelic-assisted therapy: potential benefits and challenges in mental health treatment","volume":"31","author":"Silczuk","year":"2025","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.euroneuro.2025.112746_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.nsa.2025.105516","article-title":"A review of psychedelics trials completed in depression, informed by European regulatory perspectives","volume":"4","author":"Silva","year":"2025","journal-title":"Neurosci. Appl."},{"key":"10.1016\/j.euroneuro.2025.112746_bib0026","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s40263-025-01162-y","article-title":"MDMA-assisted therapy for Post-traumatic Stress Disorder: regulatory challenges and a path forward","volume":"39","author":"Singh","year":"2025","journal-title":"CNS Drugs"},{"issue":"9","key":"10.1016\/j.euroneuro.2025.112746_bib0027","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1177\/02698811251353250","article-title":"Unequal representation? A cross-sectional analysis of age, sex, race, and ethnicity in clinical trials of classic psychedelics","volume":"39","author":"Swieczkowski","year":"2025","journal-title":"J. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.euroneuro.2025.112746_bib0028","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1055\/a-2529-7029","article-title":"Regulatory Alignment of Psilocybin Clinical Trials in Major Depressive Disorder on ClinicalTrials.gov: A Cross-Sectional Analysis","volume":"58","author":"Swieczkowski","year":"2025","journal-title":"PharmacoPsychiatry"},{"key":"10.1016\/j.euroneuro.2025.112746_bib0029","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2022.873279","article-title":"Psychedelics and psychotherapy: cognitive-behavioral approaches as default","volume":"13","author":"Yaden","year":"2022","journal-title":"Front. Psychol."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X2500820X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X2500820X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T12:32:06Z","timestamp":1771245126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X2500820X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":29,"alternative-id":["S0924977X2500820X"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2025.112746","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bridging the reporting gap: Application of the ReSPCT guidelines in psilocybin clinical trial protocols","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2025.112746","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. and ECNP. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112746"}}